Latest Period
Q2 2026
Security Snapshot
First Tracks Biotherapeutics, Inc. - Common Stock, par value $0.001 per share (TRAX) Institutional Ownership
CUSIP: 337185102
13F Institutional Holders and Ownership History for Q2 2026
Institutions Reporting
146
Shares (Excl. Options)
32,538,375
Price
$20.12
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- TRAX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 32,538,375
- Total 13F value
- $654,618,272
- Portfolio coverage rank
- 0%
- Share change
- +31,441,749
- Value change
- +$632,554,045
- Number of holders
- 146
- Shares outstanding
- 34,663,569
- SEC-reported price per share
- $35.52
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TRAX - First Tracks Biotherapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 337185102.
- 146 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q2 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 146 institutions filings for Q2 2026.
Security key
337185102
Latest holder period
Q2 2026
13F holders
146
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
TRAX full holder history
First Tracks Biotherapeutics, Inc. SEC filings
First Tracks Biotherapeutics, Inc. company facts
First Tracks Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 337185102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
TRAX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 8.3% | $101,364,593 | 2,895,304 | Chen Yu | 30 Jun 2026 | |||
| Sirenia Capital Management LP | 7.2% | $87,377,153 | 2,495,777 | Sirenia Capital Management LP | 30 Jun 2026 | |||
| FMR LLC | 5.9% | $71,915,003 | 2,054,127 | FMR LLC | 30 Jun 2026 | |||
| Affinity Asset Advisors, LLC | 5.8% | $71,140,740 | 2,032,012 | Affinity Asset Advisors, LLC | 30 Jun 2026 | |||
| BlackRock, Inc. | 5.5% | $38,617,845 | 1,919,376 | BlackRock, Inc. | 30 Jun 2026 |
As of 30 Jun 2026, 146 institutional investors reported holding 32,538,375 shares of First Tracks Biotherapeutics, Inc. - Common Stock, par value $0.001 per share (TRAX). This represents 94% of the company’s total 34,663,569 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
78%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 9.2% | 3,174,519 | 3.2% | $63,871,322 | |
| TCG Crossover Management, LLC | 8.4% | 2,895,304 | 1.4% | $58,253,516 | |
| FMR LLC | 5.9% | 2,054,127 | 0% | $41,329,045 | |
| Affinity Asset Advisors, LLC | 5.9% | 2,032,012 | 2% | $40,884,081 | |
| BlackRock, Inc. | 5.7% | 1,963,541 | 0% | $39,506,446 | |
| Trails Edge Capital Partners, LP | 4.4% | 1,514,000 | 4.8% | $30,461,680 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 1,451,909 | 0% | $29,212,409 | |
| Jupiter Topco LLC | 3.1% | 1,091,464 | 0% | 0.01% | $21,960,368 |
| Vestal Point Capital, LP | 2.9% | 1,013,000 | 0.48% | $20,381,560 | |
| Woodline Partners LP | 2.6% | 917,176 | 0.06% | $18,453,581 | |
| Sanofi | 2.4% | 821,917 | 3.1% | $16,536,970 | |
| MORGAN STANLEY | 2.3% | 781,534 | 0% | $15,724,464 | |
| 683 Capital Management, LLC | 2.2% | 750,000 | 1.4% | $15,090,001 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.1% | 729,000 | 0.02% | $14,667,480 | |
| Balyasny Asset Management L.P. | 2.1% | 714,948 | 0.03% | $14,384,754 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 702,087 | 0% | $14,128,648 | |
| BANK OF AMERICA CORP /DE/ | 1.9% | 647,962 | 0% | $13,036,996 | |
| STEMPOINT CAPITAL LP | 1.8% | 622,723 | 2.2% | $12,529,187 | |
| Palo Alto Investors LP | 1.7% | 603,489 | 1.7% | $12,142,199 | |
| Sofinnova Investments, Inc. | 1.6% | 565,199 | 0.61% | $11,371,804 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6% | 546,992 | 0% | $11,005,479 | |
| GOLDMAN SACHS GROUP INC | 1.4% | 487,213 | 0% | $9,802,725 | |
| Point72 Asset Management, L.P. | 1.2% | 408,330 | 0.01% | $8,215,600 | |
| UBS Group AG | 0.9% | 310,886 | 0% | $6,255,026 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.86% | 299,500 | 0% | $6,025,940 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q2 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 32,538,375 | $654,618,272 | +$632,554,045 | $20.12 | 146 |